Merck raises annual profit outlook as Keytruda drives profit beat

Credit: REUTERS/Brendan McDermid

Adds company outlook, compares with estimates

Oct 27 (Reuters) - Merck & Co Inc MRK.N posted a higher-than-expected quarterly profit on Tuesday and raised its full-year earnings forecast, driven by resilient demand for its blockbuster cancer therapy Keytruda during the COVID-19 pandemic.

The drugmaker's revenue took a hit at the height of the pandemic as patients avoided hospital visits, denting sales of vaccines, physician-administered drugs and animal health products.

The company said it had taken the majority of the blow in the second quarter.

Merck said it now expects full-year adjusted profit of between $5.91 and $6.01 per share, compared with its prior forecast of between $5.63 to $5.78 per share.

For 2020, Merck now expects an unfavorable impact to revenue of about $2.35 billion due to the pandemic, up from $1.95 billion it had initially estimated.

Excluding items, Merck earned $1.74 per share, beating analysts' average estimates of $1.44 per share, according to IBES data from Refinitiv.

(Reporting Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

((; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.